- Tools for Investors
- Stock News
- Investing Ideas
- Econ & Policy
- Personal Finance
Statoil (NYSE:STO) claims to have a large enough cash chest to ride out a prolonged fall in oil and gas prices, this in the context of a somewhat disappointing Q2 profit. Expects to spend $18 billion in capex in 2012.
Dow Chemical (NYSE:DOW) CEO blames a deteriorated global economy for a dismal Q2 where profits fell 34.5 percent y-on-y; sales decline by 10 percent due to Europe and the Euro. Outlook for the second half in 2012 may also be affected by a “global macro environment not improving at the rate previously anticipated.”
Potash (NYSE:POT) reports higher sales of Nitrogen (up 12.4 percent) and Potash (up 5.7 percent) against a decline of 10 percent in Phosphate. Gross margin earned on fertilizers was $1.2 billion, slightly above 2011 levels. Keeps full year outlook the same as previous.
Merck’s (NYSE:MRK) Zolinza drug, has a two-pronged effect: apart from acting on a rare type of cancer, it may also help cure AIDS. Reportedly, existing AIDS drugs are unable to kill hidden HIV-infected cells which cause a re-emergence of the disease once treatment is discontinued. Zolinza is found to have reactivated these cells in eight patients – a precursor to the complete elimination of the virus from the patient’s body.
The Libor scandal now engulfs Lloyds (NYSE:LYG) as it is sub-peonaed by investigating authorities and is already embroiled in many lawsuits connected to the issue; Libernum Capital estimates Lloyds potential liabilities at 1.5 billion pounds whereas the bank does not appear to carry any provisions to cover these penalties.
Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
There's always a bull market in some sector! Find the best opportunities in commodities.